行情

AERI

AERI

Aerie制药
NASDAQ

实时行情|Nasdaq Last Sale

18.65
+0.25
+1.36%
交易中 14:32 11/22 EST
开盘
18.40
昨收
18.40
最高
18.66
最低
18.09
成交量
32.73万
成交额
--
52周最高
50.10
52周最低
17.15
市值
8.64亿
市盈率(TTM)
-4.3120
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AERI 新闻

  • The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
  • Benzinga.6小时前
  • The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
  • Benzinga.6小时前
  • Aerie Pharmaceuticals (AERI) Investor Presentation - Sliideshow
  • Seeking Alpha - Article.8小时前
  • Aerie Pharma receives approval for Rhokiinsa in Europe
  • seekingalpha.1天前

更多

所属板块

生物技术和医学研究
+1.63%
制药与医学研究
+0.76%

热门股票

名称
价格
涨跌幅

AERI 简况

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
展开

Webull提供Aerie Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。